Marietta Wealth Management LLC Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

Marietta Wealth Management LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.2% in the second quarter, HoldingsChannel reports. The firm owned 11,451 shares of the biopharmaceutical company’s stock after purchasing an additional 673 shares during the quarter. Marietta Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,012,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Nuveen LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $343,764,000. Pacer Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock valued at $258,366,000 after buying an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Regeneron Pharmaceuticals by 171.0% during the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock valued at $305,311,000 after buying an additional 303,785 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after buying an additional 174,056 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after buying an additional 121,545 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $600.00 on Friday. The stock’s 50-day simple moving average is $572.12 and its 200-day simple moving average is $567.22. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,024.36. The company has a market capitalization of $63.59 billion, a price-to-earnings ratio of 15.12, a PEG ratio of 1.92 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the previous year, the business earned $11.56 earnings per share. The business’s revenue was up 3.6% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research note on Monday, June 9th. Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, September 27th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.